Acute renal failure related to oxaliplatin-induced intravascular hemolysis

Ulusakarya, Ayhan; Misra, Srimanta Chandra; Haydar, Mazen; Habert, Hélène; Castagné, Vincent; Gümüş, Yusuf Yasin; Delmas-Marsalet, Béatrice; Machover, D.

doi:10.1007/s12032-009-9263-3

Cited by 26 publications

(19 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Excluding the present case, seven cases of AKI have been reported after treatment with oxaliplatin (Table 4) since 1999, when the first case of hemolytic anemia with AKI was reported by Desrame et al [6][7][8][9][10][11][12]. All cases were accompanied by anemia and four cases were identified as immune-related hemolytic anemia with positive results for DAT [6,8,11,12].…”

Section: Discussionmentioning

confidence: 71%

“…All cases were accompanied by anemia and four cases were identified as immune-related hemolytic anemia with positive results for DAT [6,8,11,12]. In contrast, acute tubular necrosis was considered to be caused by direct renal toxicity from oxaliplatin in two cases [7,9] and the remaining case was reported as hemolytic uremic syndrome with negative DAT results [10].…”

Section: Discussionmentioning

confidence: 99%

“…Lee et al [5] reported that the important grade 3-4 toxicities were neutropenia (34.1 %), leukopenia (7.3 %), nausea (9.8 %), and vomiting (7.3 %). Hemolysis and renal toxicity related to oxaliplatin are quite rare, reported in only a few cases [6][7][8][9][10][11][12]. Cases with acute renal injury have been reported in only seven patients to date.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A rare case of acute kidney injury associated with autoimmune hemolytic anemia and thrombocytopenia after long-term usage of oxaliplatin

Ito

Mizuno

et al. 2012

Clin Exp Nephrol

View full text Add to dashboard Cite

Oxaliplatin is effective in advanced colorectal cancer and is known to have relatively few side effects, such as hemolysis and renal toxicity. We report a case of acute kidney injury (AKI) after treatment with a combination of oxaliplatin, folinic acid and 5-fluorouracil or capecitabine. The patient developed acute renal failure, hemolytic anemia and thrombocytopenia after the 34th course of chemotherapy including oxaliplatin. A positive direct antiglobulin test and detection of immunoglobulin G and complement C3b and C3d on erythrocytes suggested the diagnosis of immune-related severe intravascular hemolytic anemia. She was successfully treated and recovered using plasma exchange, corticosteroids and hemodialysis therapy. Only seven other cases of AKI associated with oxaliplatin use have been reported to date. As in this case, acute hemolysis due to autoimmune mechanisms and subsequent AKI occurred suddenly after frequent use of oxaliplatin in four of those cases. We should be aware that oxaliplatin may cause sudden life-threatening hemolysis by drug-induced antibodies and subsequent AKI, even though oxaliplatin is frequently administered without side effects. This represents the first case report of AKI-related hemolysis due to oxaliplatin in Japan.

show abstract

Section: Discussionmentioning

confidence: 71%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A rare case of acute kidney injury associated with autoimmune hemolytic anemia and thrombocytopenia after long-term usage of oxaliplatin

Ito

Mizuno

et al. 2012

Clin Exp Nephrol

View full text Add to dashboard Cite

show abstract

“…Daha az sıklıkla görülen ve immüntrombositopeni ve immünhemolitik anemiyi içeren tip II tepkimeler de tekrarlanan oksaliplatin infüzyonları sonrasında ortaya çıkmaktadır (5,12). Bizim olgumuzda da dördüncü kür tedavi sonrasında tip I aşırı duyarlılık tepkimesi gözlenmiş olup beşinci kür sonrasında da OİHA gelişmiştir.…”

Section: Discussionunclassified

“…Oksaliplatin ilişkili OİHA intravasküler hemoliz bulgularıyla seyreden akut bir tabloya sebep olmaktadır (4). Yüksek ve tekrarlanan oksaliplatin dozlarında hemolitik olayların görülme sıklığı artmaktadır (5). Bu yazıda, metastatik KRK tanısı ile izlenen ve oksaliplatin içeren bir kemoterapi protokolünü takiben OİHA gelişen bir olgu tartışılacaktır.…”

Section: Introductionunclassified

Oxaliplatin-induced Autoimmune Hemolitic Anemia

Yaşar¹,

Şahin²,

Sağlam³

et al. 2017

Acta Oncol Tur.

View full text Add to dashboard Cite

ÖZETOksaliplatin, onkoloji pratiğinde sık kullanılan üçüncü kuşak bir platin analoğudur. En sık görülen yan etkileri arasında bulantı, kusma, diyare, nöropati ve kemik iliği baskılanması yer almaktadır. İmmüntrombositopeni ve immün hemolitik anemi seyrek olarak bildirilmektedir. Bu yazıda, oksaliplatin ilişkili otoimmün hemolitik anemi (OİHA) gelişen bir olgu ve tedavi yaklaşımı tartışılmaktadır. Metastatik kolon kanseri tanısı ile izlenen hasta, oksaliplatin içeren bir kemoterapi protokolünü takiben başlayan kırmızı renkli idrar yapma şikâyeti ile acil servise başvurdu. Hastanın başvurusunda derin anemisi ve retikülositozunun olduğu ve serum biyokimyasının hemoliz ile uyumlu olduğu görüldü. Direk ve indirek Coombs testleri de pozitif olarak bulunan hastaya OİHA tanısı kondu. Oksaliplatinin kesilmesi ve kortikosteroid ve plazmaferez tedavisini takiben hemolizde düzelme izlendi. Oksaliplatin göreceli olarak iyi bir yan etki profiline sahip olmakla birlikte, daha seyrek görülen, ancak şiddetli seyredebilecek immün ilişkili yan etkileri gözden kaçırılmamalıdır. Anahtar Kelimeler: otoimmün hemolitik anemi, oksaliplatin, kolorektal kanser ABSTRACT Oxaliplatin is a third-generation platinum derivative, commonly used in the practice of oncology. The usual side effects include nausea, vomiting, diarrhea, neuropathy and myelosuppression. Oxaliplatin-induced immune thrombocytopenia and immune hemolytic anemia have rarely been reported. Herein, a case of oxaliplatin-induced autoimmune hemolytic anemia(AIHA) and its management have been discussed. The patient with metastatic colorectal carcinoma was admitted to the emergency room with the symptom of reddish coloration of her urine after receiving an oxaliplatin-based regimen. On her admission she had profound anemia with reticulocytosis and a serum biochemistry concordant with hemolysis. The positivity of direct and indirect Coombs tests pointed to the diagnosis of AIHA. Hemolysis improved after discontinuation of oxaliplatin and treatment with corticosteroids and plasmapheresis. Although oxaliplatin has a relatively favorable side effect profile, the possibility of less frequent, but potentially serious immune-related side effects should never be overlooked.

show abstract

A New Approach to Decrease the RES Uptake of Nanodrugs by Pre-administration with Intralipid® Resulting in a Reduction of Toxic Side Effects

Liu

2016

Intracellular Delivery III

View full text Add to dashboard Cite

Acute renal failure related to oxaliplatin-induced intravascular hemolysis

Cited by 26 publications

References 5 publications

A rare case of acute kidney injury associated with autoimmune hemolytic anemia and thrombocytopenia after long-term usage of oxaliplatin

A rare case of acute kidney injury associated with autoimmune hemolytic anemia and thrombocytopenia after long-term usage of oxaliplatin

Oxaliplatin-induced Autoimmune Hemolitic Anemia

A New Approach to Decrease the RES Uptake of Nanodrugs by Pre-administration with Intralipid® Resulting in a Reduction of Toxic Side Effects

Contact Info

Product

Resources

About